# Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)

> **NCT01168921** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 23 (actual)

## Conditions studied

- CLL
- Leukemia

## Interventions

- **DRUG:** Eltrombopag

## Key facts

- **NCT ID:** NCT01168921
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11-03
- **Primary completion:** 2022-03-07
- **Final completion:** 2022-03-07
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2023-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01168921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01168921, "Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01168921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*